Repare Therapeutics reinstated with a Buy from Accumulate at Bloom Burton

Bloom Burton analyst David Martin reinstated Repare Therapeutics with a Buy rating, up from a previous Accumulate, noting that shares are trading at half of pro-forma cash and highlighting a “broad pipeline with multiple 2024 data points.”